Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
RASH
MCID: EXN002
MIFTS: 53

Exanthem (RASH)

Categories: Infectious diseases, Skin diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Exanthem

About this section

MalaCards integrated aliases for Exanthem:

IMPROVED
Name: Exanthem 11 14 16 75
Exanthema 11 43
Rash 11 14
Rashes 41

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 31


External Ids:

Disease Ontology 11 DOID:0050486
ICD9CM 34 782.1
MeSH 43 D005076
NCIt 49 C111884
SNOMED-CT 68 112625008
ICD10 31 R21
UMLS 71 C0015230
Sources

Summaries for Exanthem

About this section

MedlinePlus: 41 A rash is an area of irritated or swollen skin. Many rashes are itchy, red, painful, and irritated. Some rashes can also lead to blisters or patches of raw skin. Rashes are a symptom of many different medical problems. Other causes include irritating substances and allergies. Certain genes can make people more likely to get rashes. Contact dermatitis is a common type of rash. It causes redness, itching, and sometimes small bumps. You get the rash where you have touched an irritant, such as a chemical, or something you are allergic to, like poison ivy. Some rashes develop right away. Others form over several days. Although most rashes clear up fairly quickly, others are long-lasting and need long-term treatment. Because rashes can be caused by many different things, it's important to figure out what kind you have before you treat it. If it is a bad rash, if it does not go away, or if you have other symptoms, you should see your health care provider. Treatments may include moisturizers, lotions, baths, cortisone creams that relieve swelling, and antihistamines, which relieve itching.

MalaCards based summary: Exanthem, also known as exanthema, is related to viral exanthem and covid-19. An important gene associated with Exanthem is CCR6 (C-C Motif Chemokine Receptor 6), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Sodium fluoride and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and bone marrow, and related phenotypes are no effect and no effect

Disease Ontology: 11 A skin disease that is characterized by a rash that results from a variety of causes including bacteria, viruses, toxins, drugs and autoimmune disorders.

Wikipedia: 75 An exanthem is a widespread rash occurring on the outside of the body and usually occurring in children.... more...
Sources

Related Diseases for Exanthem

About this section

Diseases in the Exanthem family:

Bacterial Exanthem Viral Exanthem

Diseases related to Exanthem via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1178)
# Related Disease Score Top Affiliating Genes
1 viral exanthem 32.9 TNF IL6 CRP CD8A CD4
2 covid-19 31.0 TNF IL6 IL2 EGFR CRP CCR6
3 pityriasis rosea 31.0 HLA-B CD8A CD4
4 measles 31.0 IL6 IL2 IFNA1 IFIH1
5 meningitis 30.9 TNF IL6 IL2 HLA-B CRP ALB
6 chickenpox 30.9 TNF IL6 IL2 IFNA1 GPT CTLA4
7 purpura 30.8 TNF IL6 IL2 CRP
8 drug allergy 30.8 HLA-B GPT CYP3A4 CRP CD4 ALB
9 herpes zoster 30.8 PDCD1 IL2 IFNA1 HLA-B CD8A CD4
10 rubella 30.8 TNF IL6 IL2 HLA-B GPT
11 toxic shock syndrome 30.7 TNF IL6 IL2 CRP
12 erythema multiforme 30.7 TNF IL6 IL2
13 scarlet fever 30.7 TNF IL6 CRP CD4 ALB
14 allergic disease 30.7 TNF IL6 IL2 ICOSLG H2AC18 CYP3A4
15 urticaria 30.7 TNF IL6 CRP CD4
16 vasculitis 30.7 TNF IL6 HLA-B CTLA4 CRP
17 chikungunya 30.6 TNF IL6 IFIH1 CRP
18 contact dermatitis 30.6 TNF IL6 IL2 ICOSLG CD8A CD4
19 lymphadenitis 30.6 TNF PDCD1 IL6 ICOSLG CRP CCR6
20 conjunctivitis 30.6 TNF IL6 IL2 HLA-B
21 erythema nodosum 30.6 TNF IL6 CTLA4 CRP
22 spotted fever 30.6 GPT CRP CD4
23 aseptic meningitis 30.6 TNF IL6 IFNA1 CTLA4 CRP CD8A
24 mouth disease 30.6 IL6 IFNA1 IFIH1 H2AC18 CRP CCR6
25 monkeypox 30.6 IFNA1 CD8A CD4
26 pharyngitis 30.6 TNF IL6 GPT CRP CD8A CD4
27 disseminated intravascular coagulation 30.5 TNF IL6 GPT CRP
28 glomerulonephritis 30.5 TNF IL6 CRP ALB
29 paronychia 30.5 GPT ERBB2 EGFR
30 dermatitis 30.5 TNF IL6 IL2 CTLA4 CCR6
31 hemoglobinopathy 30.5 IL6 GPT CRP CD4 ALB
32 mumps 30.5 TNF IL6 IL2 IFNA1
33 psoriasis 30.5 TNF IL6 IL2 IFIH1 HLA-B CTLA4
34 aplastic anemia 30.5 TNF IL6 H2AC18 CYP3A4 CD8A CD4
35 erysipelas 30.5 TNF IL6 IL2 ICOSLG CRP CD8A
36 viral infectious disease 30.5 TNF PDCD1 IL6 IL2 IFNA1 IFIH1
37 myelitis 30.5 TNF IL6 CCR6
38 uveitis 30.4 TNF IL6 IL2 HLA-B CTLA4
39 lung disease 30.4 TNF IL6 IFIH1 H2AC18 CCR6
40 juvenile rheumatoid arthritis 30.4 TNF IL6 IL2 ICOSLG CRP CD4
41 t-cell acute lymphoblastic leukemia 30.4 IL2 ICOSLG H2AC18 CD8A CD4 CCR6
42 meningoencephalitis 30.4 TNF IL6 CRP CD8A CD4 CCR6
43 stomatitis 30.4 TNF IL6 IL2 IFNA1 IFIH1 CD4
44 allergic contact dermatitis 30.4 TNF IL6 IL2 ICOSLG CD8A CD4
45 lymphoma, hodgkin, classic 30.4 IL2 ICOSLG H2AC18 CCR6
46 scabies 30.4 CD8A CD4 CCR6
47 dengue disease 30.4 TNF IL6 IFNA1 H2AC18 GPT CD8A
48 dermatophytosis 30.4 TNF CD4 CCR6
49 enterocolitis 30.4 TNF IL6 CRP
50 ileus 30.4 TNF IL6 CRP

Graphical network of the top 20 diseases related to Exanthem:



Diseases related to Exanthem
Sources

Symptoms & Phenotypes for Exanthem

About this section

GenomeRNAi Phenotypes related to Exanthem according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.17 ALB CCR6 CD274 CD4 CD8A CRP
2 no effect GR00402-S-2 10.17 ALB CCR6 CD274 CD4 CRP CTLA4

MGI Mouse Phenotypes related to Exanthem:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 ALB CCR6 CD274 CD4 CRP CTLA4
2 immune system MP:0005387 10.16 ALB CCR6 CD274 CD4 CD8A CRP
3 endocrine/exocrine gland MP:0005379 10.14 ALB CD4 CD8A CTLA4 EGFR ERBB2
4 normal MP:0002873 10.13 ALB CCR6 CD8A CTLA4 CYP3A4 EGFR
5 liver/biliary system MP:0005370 10.06 ALB CTLA4 EGFR IFIH1 IL2 IL6
6 cardiovascular system MP:0005385 10.06 ALB CCR6 CRP CTLA4 EGFR ERBB2
7 neoplasm MP:0002006 10.04 ALB EGFR ERBB2 IL2 IL6 PDCD1
8 digestive/alimentary MP:0005381 10.02 ALB CD4 CTLA4 EGFR ERBB2 HLA-B
9 hematopoietic system MP:0005397 9.83 CCR6 CD274 CD4 CD8A CTLA4 EGFR
10 respiratory system MP:0005388 9.76 CTLA4 EGFR ERBB2 IFNA1 IL2 IL6
11 mortality/aging MP:0010768 9.47 ALB CD274 CD4 CD8A CTLA4 CYP3A4
Sources

Drugs & Therapeutics for Exanthem

About this section

Drugs for Exanthem (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 197)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sodium fluoride Approved Phase 4 7681-49-4
2
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
3
Tocopherol Approved, Investigational Phase 4 1406-66-2
4
Menthol Approved, Experimental Phase 4 1490-04-6, 2216-51-5, 15356-60-2 1254 16666 165675
5
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
6
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
7
Nevirapine Approved Phase 4 129618-40-2 4463
8
DL-alpha-Tocopherol Approved, Experimental, Investigational, Nutraceutical, Vet_approved Phase 4 59-02-9, 10191-41-0 2116 14985
9
Isotretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4, 4759-48-2 5538 444795 5282379
10
Olaflur Experimental Phase 4 6818-37-7
11
Tocotrienol Investigational Phase 4 6829-55-6 9929901
12 Vitamin K 1 Phase 4
13 Listerine Phase 4
14 Fluorides Phase 4
15 Caseins Phase 4
16 Fluorides, Topical Phase 4
17 Anti-Inflammatory Agents Phase 4
18 Anti-Infective Agents, Local Phase 4
19 glucocorticoids Phase 4
20 Antineoplastic Agents, Hormonal Phase 4
21 Hormones Phase 4
22 Hormone Antagonists Phase 4
23 Tocotrienols Phase 4
24 Tocopherols Phase 4
25 Antioxidants Phase 4
26 Aloe Phase 4
27 Anti-Retroviral Agents Phase 4
28 Antiviral Agents Phase 4
29 Anti-HIV Agents Phase 4
30 Reverse Transcriptase Inhibitors Phase 4
31
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
32
Afamelanotide Approved, Investigational Phase 3 75921-69-6 16132954 16197727
33
Minocycline Approved, Investigational Phase 3 10118-90-8, 13614-98-7 54675783 5281021
34
Dapsone Approved, Investigational Phase 3 80-08-0 2955
35
Fusidic acid Approved, Investigational Phase 3 6990-06-3 3000226
36
Erythromycin Approved, Investigational, Vet_approved Phase 3 55-31-2, 114-07-8 12560
37
Histamine Approved, Investigational Phase 3 51-45-6 774
38
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
39
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
40
Prednisolone Approved, Vet_approved Phase 3 50-24-8 4894 5755
41
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5 1875
42
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 4159 6741
43 Coconut Approved Phase 3
44
Betamethasone Approved, Vet_approved Phase 3 378-44-9 9782
45
Desloratadine Approved, Investigational Phase 3 100643-71-8 124087
46
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 3 67-97-0, 1406-16-2 5280795 10883523
47
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7 4897
48
Dexchlorpheniramine Experimental, Investigational Phase 3 25523-97-1 33036
49
Maleic acid Experimental, Investigational Phase 3 110-16-7, 110-17-8 444266 444972
50 Provitamins Phase 3

Interventional clinical trials:

(show top 50) (show all 114)
# Name Status NCT ID Phase Drugs
1 Non-randomized Phase-IV-study to Investigate the Efficacy of FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema Unknown status NCT01315990 Phase 4 FOLFIRI + Cetuximab
2 Esthetic Effect of Casein Phosphopeptide-Amorphous Calcium Phosphate Varnish Versus Tricalcium Phosphate Varnish on Postorthodontic White Spot Lesions: A Randomized Pilot Study Unknown status NCT03217084 Phase 4 MI varnish GC;White varnish 3M
3 White Spot Lesion Development in Post-orthodontic Patients Following Weekly Application of a 1.25% Fluoride Gel Compared to Placebo Over 6 Months Completed NCT01329731 Phase 4 elmex® gelée;negative control (placebo)
4 Prospective 2-Year Longitudinal Study to Assess for Miconazole Resistance in Candida Spp. With Repeated Treatment Courses of 0.25% Miconazole Nitrate Ointment in Neonates and Infants up to 1 Year of Age With Recurrent Moderate-Severe Diaper Dermatitis Complicated by Cutaneous Candidiasis Completed NCT00702507 Phase 4 0.25 % Miconazole Nitrate Ointment
5 A Parallel, Evaluator-Blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Two Marketed Topical Skin Protectants Containing Zinc Oxide in Children With Diaper Rash Completed NCT00219466 Phase 4
6 Randomized Controlled Trial Comparing the Efficacy and Safety of Calmoseptine Ointment and Desitin Maximum Strength 40% Zinc Oxide Diaper Rash Paste in Diaper Dermatitis in Neonates and Infants Completed NCT02716415 Phase 4 Calmoseptine Ointment;Destin Maximum Strength 40% Zinc
7 A Multi-center, Double-blinded Randomized Trial for Genotype Based Personalized Prescription of Nevirapine Completed NCT00986063 Phase 4
8 A Multicenter, Randomized, Open-label, Controlled Study of Nevirapine (VIRAMUNE®) and a Short Course of Prednisone to Determine the Safety and Effectiveness of This Strategy in Preventing Nevirapine (VIRAMUNE®) Associated Rash. Completed NCT02184299 Phase 4 Nevirapine;Prednisone
9 A Randomized Control Trial to Compare Doxycycline to Isotretinoin for the Treatment of Acneiform Eruptions in Cancer Patients on Tyrosine Kinase Inhibitors Recruiting NCT04864717 Phase 4 Doxycycline 100mg po once daily x 6 months;Isotretinoin 40 mg po once daily x 6 months
10 The Healthy Baby Bottoms Study: A Trial of Theraworx Foam Formulation for the Prevention and Treatment of Diaper Dermatitis Terminated NCT04101890 Phase 4 Diaper care with Theraworx
11 Pilot Study of Acitretin for Treatment of Erlotinib-induced Skin Rash Withdrawn NCT01299220 Phase 4 Acitretin
12 A Clinical Observation to Assess the Safety and Consumers' Satisfaction of Moussik vs Desitin Creamy Ointment in Prophylaxis of Diaper Rash. A Single Blind, Multicenter, Randomized, Cross-over Study Withdrawn NCT01167465 Phase 4
13 A Phase III, Randomised, Double Blind, Placebo Controlled, Parallel Group Study, to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide (16 mg) in Patients Suffering From Polymorphic Light Eruption (PLE) Completed NCT04704713 Phase 3 Afamelanotide;Placebo
14 Phase III Randomized Double-Blind Trial of Bepanthen® Cream Versus Cetomacrogol Cream in the Prevention of Papulopustular Eruption in Patients Receiving Epidermal Growth Factor Receptor Inhibitors (EGFRI): BeCet Completed NCT01136005 Phase 3
15 A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Prophylactic Topical Sunscreen to Prevent Erlotinib- or Cetuximab-Induced Skin Rash [or Other Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Skin Rash] Completed NCT00362986 Phase 3 sunscreen
16 Effectiveness of Novel Bioactive Glass in the Treatment of Enamel White Spot Lesions : A Randomized Controlled Trial Completed NCT04401280 Phase 3 BiominF;Novamin;CPP-ACP
17 A Phase III Randomized Double-blind Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT Completed NCT01931150 Phase 3 Topical Dapsone 5% Gel;oral antibiotics
18 A Randomized, Double-blind, Prospective Trial of Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in Non-small Cell Lung Cancer Completed NCT01528488 Phase 2, Phase 3
19 A Randomized Controlled Clinical Study Comparing the Efficacy and Safety of Calmoseptine vs Destin Maximum Strength Diaper Rash Paste in Treatment of Incontinence Associated Dermatitis in Older Children and Adults Completed NCT02080247 Phase 3 Skin care regimen with Calmoseptine ointment;Skin care regimen with Destin ointment
20 A Randomized, Open Label Study to Compare the Use of the Dermatological Creams Verutex, Eritex and Fisiogel in the Management of Skin Rash Associated With Tarceva Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer. Completed NCT00718315 Phase 3 erlotinib [Tarceva];fusidic acid [Verutex];erythromycin [Eritex];Fisiogel
21 Vitamin D3 Supplementation in Polymorphic Light Eruption: Randomized Double-blinded Placebo-controlled Trial Terminated NCT01595893 Phase 3 Oral Vitamin D 3;Miglyol 812 N
22 A Double-blind, Randomized, Multicenter Parallel-group Study on Efficacy of Desloratadine and Prednisolone Association Compared to Dexchlorpheniramine and Betamethasone Association in Children (2-12 Years) With Acute Cutaneous Rash Terminated NCT01529242 Phase 3 Desloratadine + Prednisolone;Dexchlorpheniramine + Betamethasone
23 Caries Prevention Potential of Pearl Powder Versus Casein Phosphopeptide-amorphous Calcium Phosphate on Enamel White Spot Lesions: Randomized Clinical Trial. Unknown status NCT03973554 Phase 2 CPP-ACP
24 Protocol Establishment for the Prevention of Lamotrigine-induced Skin Rash in Epilepsy Patients: A Pilot Study Unknown status NCT03220256 Phase 2 Lamotrigine
25 A Phase II Randomized, Double Blind, Placebo Study to Evaluate the Efficacy of Vitamin K1 Cream Treatment Compared to Placebo for the Prevention of Papulo-pustular Rash in Metastatic Colorectal Patients Receiving First Line EGFRI Treatment. Unknown status NCT01763307 Phase 2 RECONVAL CREAM;PLACEBO
26 Phase II Study to Evaluatate the Efficacy of Gemcitabine Plus Erlotinib for RASH-positive Patients With Metastatic Pancreatic Cancer and Friendly Risk Circumstances Unknown status NCT01729481 Phase 2 Gemcitabine;Erlotinib;Oxaliplatin;Folinic Acid;Irinotecan;5-FU
27 Double Blind Placebo Controlled Trial, for Evaluating Preventive Therapy With Either Oint Threolone Versus Synthomycine Versus Aqua Cream, for EGFR'I Induced Acneiform Rash Completed NCT01256437 Phase 2 Threolone ointment;ointment Synthomycine;Aqua cream
28 Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor Completed NCT03440515 Phase 2 Prednisone
29 A Phase 2, Open-label, Randomized Clinical Trial of Skin Toxicity Treatment in Subjects Receiving Second-line FOLFIRI or Irinotecan Only Chemotherapy Concomitantly With Panitumumab Completed NCT00332163 Phase 2 Irinotecan;FOLFIRI;Pre-emptive Skin Treatment;Reactive Skin Treatment
30 A Randomized, Double-blind, Placebo-controlled Trial of AC-701 for Treatment of Skin Rash in Subjects With EGFR Inhibitor Therapy Completed NCT04239846 Phase 2 AC-701 Topical Gel 0.3%
31 Phase II, Open-label, Single Blind, Randomised Clinical Trial With Tetracycline as a Prophylaxis for Rash and Dermatological Recommendations Versus Dermatological Recommendations in Patients With NSCLC Receiving Treatment With BIBW 2992 Completed NCT01880515 Phase 2 Tetracycline
32 A Randomized Controlled Trial of Systemic and Topical Treatments for Rash Secondary to Erlotinib in Advanced Stage IIIB or IV Non-Small Cell Lung Cancer Completed NCT00473083 Phase 2 Minocycline;Clindamycin 2% in hydrocortisone 1% lotion;Erlotinib;Topical clindamycin 2%, triamcinolone acetonide 0.1% soln
33 A Safety, Tolerability and Efficacy Study of Doxycycline Topical Foam Administered Topically for Prevention of Epidermal Growth Factor Receptor Inhibition Skin Toxicity, to Subjects With Cancer Receiving Cetuximab or Panitumumab Completed NCT02239731 Phase 2 FDX104 (4% Doxycycline)
34 A Multi-Center Study Investigating the Correlation Between TARCEVA ®-Induced Rash and Efficacy Among EGFR-mutated NSCLC Patients Receiving First-line Therapy Completed NCT01174563 Phase 2 erlotinib [Tarceva]
35 A Randomized, Open-label, Dose-escalation to Rash Study to Assess the Effect of Tarceva in Combination With Gemcitabine on Overall Survival in Patients With Metastatic Pancreatic Cancer. Completed NCT00652366 Phase 2 Erlotinib, escalating dose;Erlotinib, standard dose;Gemcitabine
36 A Phase II Trial Assessing Metronidazol Actavis 1% Topical Cream in the Prevention and Treatment of Erlotinib Associated Rash Completed NCT00642473 Phase 2 Erlotinib;Metronidazole Actavis
37 A Randomized, Open Label Study to Evaluate the Effect of Doxycycline on Tarceva-induced Skin Rash in Patients With Non-small Cell Lung Cancer After Failure of First Line Chemotherapy Completed NCT00531934 Phase 2 Doxycline;erlotinib [Tarceva]
38 An Open Label Study of Tarceva in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas : Relationship Between Skin Rash and Survival Completed NCT00461708 Phase 2 Erlotinib;Gemcitabine
39 A Two-Part, Phase II Randomized Trial to Explore Topical Spironolactone to Prevent/Attenuate Rash From Epidermal Growth Factor Receptor Inhibitors (Panitumumab and Cetuximab) in Advanced Cancer Patients Completed NCT01867294 Phase 2 Doxycycline;Spironolactone;Sunscreen;Therapeutic Hydrocortisone
40 Preemptive Therapy Study of Cetuximab(Erbitux®)Induced Skin Rash Using Doxycycline, Sunscreen, Hydrocortisone and Moisturizer in Colorectal and Head and Neck Cancer Patients Recruiting NCT01874860 Phase 2 Doxycycline;Hydrocortisone 1% cream;Clindamycin;Medrol-dose pack (Steroid)
41 A Randomized Phase II Study of Topical Steroids as Preemptive Therapy for Epidermal Growth Factor Receptor Inhibitor-Induced Papulopustular Eruption Recruiting NCT03115567 Phase 2 Triamcinolone
42 A Multi-center, Randomized, Double-blind, Placebo-controlled, Therapeutic Exploratory, Phase II Clinical Trial for the Efficacy Investigation and Safety Evaluation of DWP708 Recruiting NCT05378360 Phase 2
43 An Open-label Study for Assessing the Efficacy and Safety of Nicotinamide Treatment for Lupus-associated Skin Lesions in Patients With Cutaneous Lupus Erythematosus or Systemic Lupus Erythematosus Active, not recruiting NCT03260166 Phase 2 nicotinamide
44 A Phase 1b/2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of ATR-04 to Reduce the Severity of Epidermal Growth Factor Inhibitor Associated Papulopustular Rash Suspended NCT04731259 Phase 1, Phase 2 ATR-04
45 1% Topical Pimecrolimus Cream for the Prevention of Rash Associated With the Use of the EGFR Antagonist, Cetuximab Terminated NCT01692626 Phase 2 Pimecrolimus;Placebo
46 Four-arm Study to Evaluate Urea 40% Cream, Fluocinonide 0.05% Cream, Tazarotene 0.1% Cream, and an Emollient Cream for the Treatment of Hand-foot Skin Reaction Related to the Use of Multi-targeted Tyrosine Kinase Inhibitor Sorafenib. Terminated NCT00667589 Phase 2 urea 40% cream;fluocinonide 0.05% cream;tazarotene 0.1% cream;bland emollient cream (Udderly smooth® Udder Cream)
47 A Phase II, Randomized, Double-Blind, Parallel Design Study to Evaluate ACZONE™ (Dapsone) Gel, 5% As a Treatment For Rash Related to the Human Epidermal Growth Factor Receptor 1 (HER1)/Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor Tarceva® (Erlotinib) Terminated NCT00343187 Phase 2 ACZONE (dapsone) Gel, 5%;Vehicle Control
48 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Acneiform Rash in Subjects With Cancer Receiving EGFRi or MEKi Therapy Terminated NCT04697069 Phase 2
49 A Phase II Trial of Single-agent Cetuximab Dose Escalated to Rash in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma Terminated NCT00082212 Phase 2
50 A Phase 1, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Safety, Tolerability, and Systemic Absorption of Menadione Topical Lotion as an Emergent and Pre-emergent Treatment for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash Completed NCT00656786 Phase 1 Menadione Topical Lotion

Search NIH Clinical Center for Exanthem

Cochrane evidence based reviews: exanthema

Sources

Genetic Tests for Exanthem

About this section
Sources

Anatomical Context for Exanthem

About this section

Organs/tissues related to Exanthem:

MalaCards : Skin, Lung, Bone Marrow, Breast, T Cells, Liver, Myeloid
Sources

Publications for Exanthem

About this section

Articles related to Exanthem:

(show top 50) (show all 35951)
# Title Authors PMID Year
1
Prevalence of arboviruses and other infectious causes of skin rash in patients treated at a tertiary health unit in the Brazilian Amazon. 62 41
36228027 2022
2
Safety of routine childhood vaccine coadministration versus separate vaccination. 62 41
36162867 2022
3
Oral manifestations of monkeypox: Brief review. 62 41
36206497 2022
4
Liver protection and hemostatic effects of medicinal plant Arnebia euchroma (Royle) I.M.Johnst extract in a rat model. 62
36126784 2023
5
Severe symptomatic nickel allergy following stent graft implantation requiring excision and external iliac artery reconstruction. 62
36248398 2022
6
A prospective randomized comparison of the efficacy of standard antiviral therapy versus ultrasound-guided thoracic paravertebral block for acute herpes zoster. 62
35107389 2022
7
Assessment of antifungal efficacy of itraconazole loaded aspasomal cream: comparative clinical study. 62
35506466 2022
8
Measles outbreak in Semuto Subcounty, Nakaseke District, Uganda, June-August 2021. 62
36188443 2022
9
Atypical presentation of sexually-transmitted monkeypox lesions. 62
36102117 2022
10
Natural history of Sudan ebolavirus infection in rhesus and cynomolgus macaques. 62
35657325 2022
11
A case report of monkeypox as a result of conflict in the context of a measles campaign. 62
36133748 2022
12
Monkeypox virus emerges from the shadow of its more infamous cousin: family biology matters. 62
35751396 2022
13
Monkeypox 2022 Identify-Isolate-Inform: A 3I Tool for frontline clinicians for a zoonosis with escalating human community transmission. 62
36249992 2022
14
Use of M-M-R II outside of the routinely recommended age range - a systematic literature review. 62
34128759 2022
15
Surveillance on the adverse events following immunization with the pentavalent vaccine in Zhejiang, China. 62
35108152 2022
16
PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy. 62
35857126 2022
17
Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies: results from a cohort from China. 62
35859245 2022
18
Venetoclax-induced vitiligo in a patient with chronic lymphocytic leukemia. 62
36255070 2022
19
Have the prevalence of eczema symptoms increased in the Mexican pediatric population? Prevalence and associated factors according to Global Asthma Network Phase I. 62
36267354 2022
20
Pneumonia caused by toxic epidermal necrolysis. 62
36204458 2022
21
Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody) in patients with metastatic non-small cell lung cancer harboring EGFR Exon20ins: towards a proactive, multidisciplinary approach. 62
36198244 2022
22
Pembrolizumab-induced rash in a patient with angiosarcoma. 62
36186410 2022
23
Impact of Prior Drug Allergies on the Risk, Clinical Features, and Outcomes of Idiosyncratic Drug-Induced Liver Injury in Adults. 62
35122190 2022
24
Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial. 62
35678328 2022
25
Retinal vasculopathy following varicella zoster virus infection. 62
36165416 2022
26
A Spotlight on Drug-Induced Vasculitis. 62
36129631 2022
27
A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults. 62
35290152 2022
28
Monkeypox and Herpes Simplex Virus Type 2 Coinfection: Case Report of Perianal Lesions in HIV-Positive Patient. 62
35948285 2022
29
Syndromic Surveillance as a Tool for Case-Based Varicella Reporting in Georgia, 2016-2019. 62
34644188 2022
30
Molecular epidemiology of enteroviruses associated with hand, foot, and mouth disease in South India from 2015 to 2017. 62
35970888 2022
31
The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison. 62
36028656 2022
32
A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma. 62
36113242 2022
33
New Indication for Cancer Drug Crizotinib. 62
36261901 2022
34
Incidence and outcomes of adverse drug reactions to first-line anti-tuberculosis drugs and their effects on the quality of life: A multicenter prospective cohort study. 62
35909258 2022
35
Syphilitic Folliculitis: A Case Report With Demonstration of Spirochetes Showing Follicular Epitheliotropism. 62
35925589 2022
36
Growth and micronutrient levels of 6-12 years-old children with food allergies, food sensitisation, and food restrictions. 62
35869575 2022
37
Still disease with persistent atypical dermatomyositis-like skin eruption: two cases associated with macrophage activation syndrome. 62
35703021 2022
38
Mycobacterium marinum cellulitis: A fishy etiology. 62
36008223 2022
39
Impact of Patient-Reported Penicillin Allergy on Antibiotic Prophylaxis and Surgical Site Infection Among Patients Undergoing Colorectal Surgery. 62
34856589 2022
40
Monkeypox: A focused narrative review for emergency medicine clinicians. 62
36030595 2022
41
[Apalutamide, Erleada®]. 62
36226398 2022
42
Case of recurring Kikuchi disease and autoimmune hepatitis. 62
36267822 2022
43
Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease. 62
35078234 2022
44
Applicability and benefits of telemedicine in the monitoring of monkeypox close contacts. 62
36245389 2022
45
Characterization of Mayaro virus (strain BeAn343102) biology in vertebrate and invertebrate cellular backgrounds. 62
36215156 2022
46
Dermatologic Symptoms and Syndromes Associated with Headache. 62
36066692 2022
47
Case of Secondary Syphilis with Mucocutaneous, Articular, and Pulmonary Involvement in a 74-Year-Old Moroccan Man. 62
36242512 2022
48
Monkeypox: An emerging global threat during the COVID-19 pandemic. 62
35970757 2022
49
The Efficacy and Safety of The Innovative Cold Atmospheric-Pressure Plasma Technology in The Treatment of Striae Distensae: A Randomized Controlled Trial. 62
36217555 2022
50
Clinical Manifestations of Varicella: Disease Is Largely Forgotten, but It's Not Gone. 62
36265857 2022
Sources

Variations for Exanthem

About this section
Sources

Expression for Exanthem

About this section
Search GEO for disease gene expression data for Exanthem.
Sources

Pathways for Exanthem

About this section

Pathways related to Exanthem according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.8 CCR6 CD274 CD4 CD8A CRP CTLA4
2
Akt Signaling 64
Show member pathways
 13.36 TNF IL6 IL2 ERBB2 EGFR CD4
3
PAK Pathway 64
Show member pathways
 13.23 CCR6 CD4 EGFR ERBB2 IL2 IL6
4
Toll-like receptor signaling pathway 74
Show member pathways
 12.79 TNF IL6 IL2 IFNA1 IFIH1
5
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.57 EGFR HLA-B IFNA1 IL2 IL6 TNF
6
Immune response IL-23 signaling pathway 22
Show member pathways
 12.5 TNF IL6 IL2 ERBB2 EGFR CD4
7
CD28 co-stimulation 66
Show member pathways
 12.31 PDCD1 ICOSLG CTLA4 CD8A CD4 CD274
8
CD28 Signaling in T-Helper Cell 64
Show member pathways
 12.19 IL2 ICOSLG CTLA4 CD4
9
NF-kappaB Signaling 3
12.07 TNF PDCD1 IL2 IFNA1 IFIH1 CTLA4
10
Spinal cord injury 74
11.94 TNF IL6 IL2 EGFR
11
Hematopoietic Stem Cells and Lineage-specific Markers 65
11.94 TNF IL6 IL2 CD8A CD4
12
IL27-mediated signaling events 61
Show member pathways
 11.86 TNF IL6 IL2 CD4
13
Allograft rejection 74
11.81 CTLA4 HLA-B IL2 TNF
14
T-cell activation SARS-CoV-2 74
Show member pathways
 11.81 TNF PDCD1 IL2 CTLA4 CD8A CD4
15
Phosphorylation of CD3 and TCR zeta chains 66
Show member pathways
 11.72 PDCD1 CD4 CD274
16
Acute viral myocarditis 74
11.7 IL6 IL2 CD4
17
Network map of SARS-CoV-2 signaling pathway 74
Show member pathways
 11.7 IL6 CRP CD8A CD4
18
Th17 cell differentiation pathway 74
11.66 IL6 IL2 CD4
19
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 61
Show member pathways
 11.64 TNF IL2 CTLA4
20
Innate Lymphoid Cells Differentiation 65
11.62 TNF IL2 CD8A CD4 CCR6
21
Photodynamic therapy-induced NF-kB survival signaling 74
Show member pathways
 11.61 TNF IL6 IL2
22
Inflammatory bowel disease signaling 74
Show member pathways
 11.57 TNF IL6 IL2
23
SHP2 signaling 61
11.52 IL6 IL2 EGFR
24
Dendritic Cells Developmental Lineage Pathway 65
11.52 CD4 CD8A IL2 IL6 TNF
25
Interactions between immune cells and microRNAs in tumor microenvironment 74
11.46 PDCD1 CTLA4 CD274
26
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.42 TNF IL6 CYP3A4
27
Cytokines and inflammatory response 74
11.2 TNF IL6 IL2 CD4
28
Prostaglandin signaling 74
11.19 TNF IL6 IFNA1
29
Cancer immunotherapy by PD-1 blockade 74
11.09 PDCD1 CD8A CD274
30
T cell receptor and co-stimulatory signaling 74
11.08 PDCD1 IL2 CTLA4 CD8A
31
Overview of nanoparticle effects 74
10.98 TNF IL6 CRP
32
Extrafollicular B cell activation by SARS-CoV-2 74
10.95 TNF PDCD1 IL6 IL2 ICOSLG CRP
33
RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) 66
10.66 IL2 CTLA4
34
COVID-19 adverse outcome pathway 74
10.65 IL6 IL2
35
Cells and molecules involved in local acute inflammatory response 74
Show member pathways
 10.3 TNF IL6
Sources

GO Terms for Exanthem

About this section

Cellular components related to Exanthem according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005887 10.03 TNF HLA-B ERBB2 EGFR CTLA4 CD8A
2 plasma membrane GO:0005886 10.03 TNF HLA-B ERBB2 EGFR CTLA4 CD8A
3 external side of plasma membrane GO:0009897 9.53 TNF PDCD1 ICOSLG CTLA4 CD8A CD4

Biological processes related to Exanthem according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 10.06 TNF IL2 ERBB2 EGFR CD4
2 immune response GO:0006955 10.06 CCR6 CD274 CD4 CD8A CTLA4 HLA-B
3 positive regulation of kinase activity GO:0033674 9.97 IL2 ERBB2 EGFR CD4
4 humoral immune response GO:0006959 9.96 TNF PDCD1 IL6 IFNA1 CCR6
5 defense response GO:0006952 9.91 TNF IFNA1 ICOSLG HLA-B
6 negative regulation of lipid storage GO:0010888 9.8 CRP IL6 TNF
7 immune system process GO:0002376 9.61 PDCD1 IL2 IFIH1 ICOSLG HLA-B CTLA4
8 adaptive immune response GO:0002250 9.58 PDCD1 IL2 IFNA1 ICOSLG HLA-B CTLA4
Sources

Sources for Exanthem

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....